TXMD
TherapeuticsMD, Inc.
There isn't enough reported data to score TXMD yet.
UNH
UnitedHealth Group Incorporated
UNH's fundamentals are mixed: free cash flow grew 31%, but earnings per share fell 8.5%. At 23x earnings, it's trading right at its usual valuation. Analysts expect strong earnings growth, though they disagree widely on how much.
TXMD Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Strong | |
| Strong |
TXMD's cash flow and balance sheet are currently strong, but its profitability is weak. There isn't enough data to rate its revenue.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
TXMD PE Valuation
TXMD has no meaningful PE right now: it lost money over the past year.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH's PE is in its fair range at 23x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
TXMD Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong growth | |
| -- | |
| Limited | |
| High |
Analysts expect TXMD's revenue to grow, with its earnings and profitability holding steady.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
Analysts expect UNH's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
TXMD Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$0.02 | +$0.03 |
| Q1 2026 | $0.02 | +$0.21 |
| Q4 2025 | -$0.05 | +$0.14 |
| Q3 2025 | $0.01 | +$0.26 |
| Q2 2025 | -$0.05 | +$0.47 |
| Q1 2025 | -$0.19 | +$0.48 |
| Q4 2024 | -$0.19 | +$0.79 |
| Q3 2024 | -$0.25 | -103% |
TXMD lost $0.02 per share over the past year, a smaller loss than the year before.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH has the edge over TXMD on earnings quality, reporting a profit while its opponent remains loss making.
TXMD Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $869K | -8.7% |
| Q1 2026 | $724K | +84% |
| Q4 2023 | $502K | -56% |
| Q2 2023 | $437K | -98% |
| Q1 2023 | $416K | -98% |
| Q4 2022 | $1.2M | -94% |
| Q3 2022 | $20.9M | -18% |
| Q2 2022 | $28.6M | +24% |
TXMD's revenue is growing: $869,000 last quarter, down 8.7% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -94% | -21 points |
| Q1 2026 | -100% | +122 points |
| Q4 2025 | -174% | N/A |
| Q3 2025 | -110% | N/A |
| Q2 2025 | -73% | N/A |
| Q1 2025 | -222% | N/A |
| Q4 2023 | -321% | -6138 points |
| Q2 2023 | -566% | -500 points |
TXMD's operating margin was −94% last quarter, down 21 points from the same quarter a year ago.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH has the edge over TXMD on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH has the edge over TXMD on profitability, with a higher operating margin.
TXMD Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $779K | +104% |
| Q1 2026 | $944K | +35% |
| Q4 2025 | $375K | +2106% |
| Q3 2025 | $999K | +$1.1M |
| Q2 2025 | $381K | -74% |
| Q1 2025 | $699K | +$928K |
| Q4 2024 | $17K | +$5M |
| Q3 2024 | -$71K | +$2.4M |
TXMD has the edge over UNH on cash flow, with more consistent year-over-year improvement.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH still generates free cash flow, though less than at its 2022 peak: $22.8B over the past year.
TXMD Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.6% | +74K shares |
| 1 year | +0.8% | +91K shares |
| 3 years | +24% | +2.3M shares |
| 5 years | +114% | +6.2M shares |
| Available history | +141% | +6.8M shares |
TXMD has 12M diluted shares, up 0.8% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2023 | — |
UNH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -4M shares |
| 1 year | -0.7% | -6M shares |
| 3 years | -3.6% | -34M shares |
| 5 years | -5.5% | -53M shares |
| Available history | -6.6% | -64M shares |
UNH has the edge over TXMD on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3.4B |
| Q2 2026 | $1.6B |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $2.5B |
| Q1 2025 | $3B |
| Q4 2024 | $5B |
UNH spent $5B buying back its own shares over the past year, down 52% from the year before.
TXMD Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2023 | -0.0x | Net Cash |
| Q2 2023 | -0.3x | Net Cash |
| Q1 2023 | -0.7x | Net Cash |
| Q4 2022 | -16.0x | Net Cash |
TXMD has more cash than debt.
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH's net debt is about 1.7 years of its operating earnings (EBITDA), about the same as a year ago.
TXMD Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 41.0 | Neutral |
| Stochastic | 18.2 | Oversold |
TXMD's weekly RSI is 41 (neutral) and its Stochastic is 18 (oversold).
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
TXMD PE vs Healthcare Sector
| Metric | TXMD | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
TXMD has no meaningful PE right now: it lost money over the past year.
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH is trading at 23x earnings, a 11% discount to the Healthcare sector's median of 26x.
TXMD Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.90 | 4.2% below |
| 20 week MA | $2.02 | 9.9% below |
| 50 week MA | $2.06 | 12% below |
| 100 week MA | $1.62 | 12% above |
| 200 week MA | $2.20 | 17% below |
TXMD's trend is mixed: it's above one of its five weekly moving averages, and 17% below its 200-week average.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has the edge over TXMD on trend strength, trading above more of its moving averages.
TXMD Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $120.5 | $59.5 | -51% |
| 2021 | $59.5 | $20.5 | -66% |
| 2022 | $20.5 | $5.62 | -73% |
| 2023 | $5.62 | $2.25 | -60% |
| 2024 | $2.25 | $1.09 | -52% |
| 2025 | $1.09 | $1.74 | +60% |
| 2026 YTD | $1.74 | $1.82 | +4.6% |
TXMD has finished lower in five of the last six years. It's up 4.6% so far in 2026.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has the edge over TXMD on returns for 2026, with the stronger performance.